MacroGenics, Inc.
MGNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $148 | $57 | $150 | $76 |
| % Growth | 159.4% | -61.9% | 98.3% | – |
| Cost of Goods Sold | $12 | $8 | $7 | $3 |
| Gross Profit | $136 | $49 | $143 | $73 |
| % Margin | 91.7% | 85.6% | 95.1% | 96.5% |
| R&D Expenses | $177 | $167 | $207 | $215 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $71 | $52 | $59 | $63 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$2 | -$2 | -$2 |
| Operating Expenses | $247 | $217 | $264 | $276 |
| Operating Income | -$111 | -$168 | -$121 | -$203 |
| % Margin | -74.5% | -294.2% | -80.9% | -268.1% |
| Other Income/Exp. Net | $45 | $159 | $2 | $1 |
| Pre-Tax Income | -$66 | -$9 | -$120 | -$202 |
| Tax Expense | $1 | $0 | $0 | $0 |
| Net Income | -$67 | -$9 | -$120 | -$202 |
| % Margin | -45.1% | -15.8% | -79.8% | -267.2% |
| EPS | -1.07 | -0.15 | -1.95 | -3.18 |
| % Growth | -613.3% | 92.3% | 38.7% | – |
| EPS Diluted | -1.07 | -0.15 | -1.95 | -3.18 |
| Weighted Avg Shares Out | 63 | 62 | 61 | 60 |
| Weighted Avg Shares Out Dil | 63 | 62 | 61 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $10 | $2 | $1 |
| Interest Expense | $1 | $1 | $0 | $0 |
| Depreciation & Amortization | $8 | $10 | $12 | $11 |
| EBITDA | -$57 | $2 | -$108 | -$191 |
| % Margin | -38.7% | 3.5% | -71.9% | -252.3% |